Sugi Predict

Sugi Predict / Compounds / SCHEMBL19259372

SCHEMBL19259372

SCHEMBL19259372

CC(C)OC(=O)CC1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ CTSK P43235 3/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MIF P14174 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ SLC1A3 P43003 1/20 0.37
▸ SLC1A2 P43004 1/20 0.37
▸ SLC1A1 P43005 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7569020 0.98 L3MBTL1 (0.47) L3MBTL1TDP1CTSKCTSLCTSB
SCHEMBL11093892 0.84 L3MBTL1 (0.43) L3MBTL1TDP1CTSKCTSLCTSB
SCHEMBL11093213 0.84 L3MBTL1 (0.43) L3MBTL1TDP1CTSKCTSLCTSB
SCHEMBL29210828 0.84 SHBG (0.36) L3MBTL1TDP1ALDH1A1LMNANPSR1
SCHEMBL29080682 0.84 LMNA (0.36) L3MBTL1TDP1ALDH1A1LMNAEPHX1
SCHEMBL25160053 0.82 L3MBTL1 (0.45) L3MBTL1TDP1CTSKCTSLCTSB
SCHEMBL9100868 0.82 L3MBTL1 (0.45) L3MBTL1TDP1CTSKCTSLCTSB
SCHEMBL2972978 0.82 L3MBTL1 (0.45) L3MBTL1TDP1CTSKCTSLCTSB
SCHEMBL30304705 0.82 LMNA (0.35) L3MBTL1TDP1ALDH1A1LMNANPSR1
SCHEMBL9444266 0.82 L3MBTL1 (0.45) L3MBTL1TDP1CTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416612-B1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2022-12-28 — — EP claimed
CN-109069378-B Perfume mixture containing ester and ketone 西姆莱斯股份公司 2022-10-11 — — CN claimed
US-20190136148-A1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2019-05-09 — — US claimed
EP-3416612-A1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES Symrise AG (DE) 2018-12-26 — — EP claimed
CN-109069378-A spice mixture containing ester and ketone 西姆莱斯股份公司 2018-12-21 — — CN claimed
WO-2017140336-A1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2017-08-24 — — WO claimed
US-20230357319-A1 PROTEASOME INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-11-09 — — US disclosed
US-11713335-B2 Aminocoumarin compounds and methods of their use PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-08-01 — — US disclosed
US-11713335-B2 Aminocoumarin compounds and methods of their use PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-08-01 — — US disclosed
EP-3416612-B1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2022-12-28 — — EP disclosed
EP-3416612-B1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2022-12-28 — — EP disclosed
CN-109069378-B Perfume mixture containing ester and ketone 西姆莱斯股份公司 2022-10-11 — — CN disclosed
US-20210009621-A1 AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2021-01-14 — — US disclosed
EP-3416612-A1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES Symrise AG (DE) 2018-12-26 — — EP disclosed
CN-109069378-A spice mixture containing ester and ketone 西姆莱斯股份公司 2018-12-21 — — CN disclosed
US-9884860-B2 Fused pyrroledicarboxamides and their use as pharmaceuticals SANOFI (FR) 2018-02-06 — — US disclosed
WO-2017140336-A1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2017-08-24 — — WO disclosed
WO-2017140336-A1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2017-08-24 — — WO disclosed
US-20160159793-A1 Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals SANOFI (FR) 2016-06-09 — — US disclosed
US-9284333-B2 Fused pyrroledicarboxamides and their use as pharmaceuticals SANOFI (FR) 2016-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210009621-A1 AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE AAAS, PROC, AADAC L3MBTL1 3356/4885TDP1 2795/4885CTSK 743/4885
US-20190136148-A1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES FASN, CETP, FAM120A L3MBTL1 3105/4885TDP1 4734/4885CTSK 1783/4885
US-20160159793-A1 Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals KCNA1, KCNE1, KCNH1 L3MBTL1 2319/4885TDP1 404/4885CTSK 3539/4885
US-11713335-B2 Aminocoumarin compounds and methods of their use AAAS, PROC, AADAC L3MBTL1 3356/4885TDP1 2795/4885CTSK 743/4885
US-20230357319-A1 PROTEASOME INHIBITORS PSMG3, PSME1, PSMB1 L3MBTL1 1520/4885TDP1 1633/4885CTSK 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.